k‑Anonymity vs Differential Privacy in Healthcare: When to Use Which?

You can start with basic EHR literacy (what encounters, diagnoses, and labs mean), but you’ll need collaboration with domain experts to avoid harmful modeling choices (label leakage, invalid outcomes, misinterpreting risk). Privacy decisions also depend on the clinical context, what’s sensitive, who can access, and how outputs are used.

It’s risky. Public release assumes strong adversaries with auxiliary datasets and repeated analyses. k‑anonymity can reduce obvious linkage risk but doesn’t provide the robust guarantee DP is designed for. If “public” is truly the goal, DP is usually the safer default.

HIPAA provides pathways and guidance, but “safe” depends on context, threat model, and how data is shared. Linkage attacks and auxiliary information can still create risk, which is why expert determination and strong governance matter.

DP is most naturally suited to aggregate releases and DP-trained models rather than high-fidelity microdata. There are DP synthetic data approaches, but they require careful design and often trade substantial accuracy for privacy. If you need row-level sharing, controlled environments and contractual governance are still central.

There’s no universal value. ε choices depend on sensitivity, population size, number of releases (composition), and harm models. The most defensible approach is to follow formal guidance for evaluating DP systems, bound contributions, and treat ε as a governed resource rather than a magic constant.